Why Biotech Struggles to Finish What It Starts
Summary:
Researchers use artificial intelligence to rapidly design potent antibodies that can both block and activate G protein-coupled receptors, revolutionizing drug development.Biotech doesn’t typically fail in the lab. It fails later — after early promise and before approval — when the cost of proving a drug works comes up against a funding system built for an earlier stage.
How much of the scientific literature is generated by AI?
Summary:
Research indicates a rapid surge in AI-generated literature. One study found that submissions with >70% AI text doubled since 2024, while another reported AI-generated content in computer science preprints rose from 7% to 43% by 2025. Approximately one in eight biomedical papers now contains AI-generated text.
Drugs from China are reshaping biotech. Track the licensing deals here.
Summary:
Biopharmaceutical firms in the U.S. and Europe are increasingly turning to China’s biotech sector for new medicines. Follow this year’s dealmaking with this database.
The American Biotech Innovation Alliance launches to unify domestic strategy amid global competition
Summary:
The American Biotech Innovation Alliance (ABIA) has launched to establish a unified national strategy for U.S. biotech leadership. Uniting 21 founding members, the nonprofit focuses on regulatory policy and manufacturing to address global competition and secure domestic supply chains.
NIH grant cuts disproportionately hit minority and female scientists
Summary:
A survey reveals sharp divides in who bore the brunt of last year’s spree of grant cancellations by the Trump administration.
